US Stock Market Move | Launching the next generation cancer immunotherapy platform HCW Biologics (HCWB.US) surged nearly 70%.

On Monday, HCW Biologics (HCWB.US) surged nearly 70%, reaching $5.81 per share. In terms of news, the company reported that its scientists have developed a second-generation immune therapy drug based on anti-CD279 monoclonal antibodies, targeting solid tumors, particularly pancreatic cancer and ovarian cancer, using their novel proprietary TRBC product discovery and development platform technology. Since its introduction in 2011 for cancer treatment, immune checkpoint inhibitors (ICIs) have been hailed as a groundbreaking cancer therapy. Immune checkpoint proteins are expressed on the surface of T cells, acting as regulatory factors that inhibit excessive T cell activation. However, preclinical and clinical studies highlighted by the company on Monday suggest that ICIs lack immune cell co-stimulatory activity, thereby reducing their anti-tumor efficacy.